Inmode Ltd

InMode Ltd. designs, develops, manufactures and markets minimally-invasive aesthetic medical products. It also designs, develops, manufactures and markets non-invasive medical aesthetic products that target a array of procedures including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture and superficial benign vascular and pigmented lesions. The company was founded by Moshe Mizrahy and Michael Kreindel on January 2, 2008 and is headquartered in Yokneam, Israel.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

InMode reports record revenue, plans global expansion for growth

InMode's strong financial performance in Q4 and full year 2022, driven by successful product launches and global expansion efforts, positions the company for continued growth. Despite challenges in pinpointing market penetration, opportunities lie in new product launches and untapped physician markets.

InMode reports robust Q1 earnings, eyes international expansion and talent

InMode delivered strong Q1 2023 results, driven by revenue growth, international expansion, and strategic hiring practices, positioning the company for continued success.
While facing challenges such as rising operating expenses and talent acquisition complexities, InMode's focus on quality, innovation, and financial strength presents opportunities for sustainable growth.
By leveraging opportunities in talent acquisition, product innovation, and international expansion, InMode can enhance market competitiveness and drive long-term value creation.
Overall, InMode's performance, strengths, and strategic outlook indicate a positive trajectory for future growth and profitability, supported by a solid financial foundation.

InMode achieves record Q2 earnings, eyes global expansion and innovation

InMode's strong financial performance, global expansion, and focus on innovation position it well for future growth. While facing challenges in managing increased expenses and scaling sales, the company's strategic investments and market positioning offer promising opportunities for expansion and market leadership.

InMode reports steady Q3 growth amidst challenges and opportunities

InMode's Q3 performance reflects resilience amid industry seasonality and macro challenges, with revenue growth and strong margins.
The company's focus on innovation, IP protection, and strategic acquisitions positions it for sustained leadership and growth.
Challenges in leasing processes and legal battles require proactive management, but opportunities in M&A and product growth remain.
Despite uncertainties for 2024, InMode's strategic initiatives and market presence offer a foundation for future success.

InMode reports record 2023 revenue, eyes international expansion and M&A

InMode navigated industry challenges in 2023 with resilience, focusing on innovation, global expansion, and cost management. Despite facing headwinds, the company remains optimistic about growth opportunities, leveraging its strong financial position and strategic initiatives for future success.

InMode reports Q1 revenue of $80.3M, adjusts guidance for 2024

InMode faces challenges from industry headwinds and manufacturing delays but shows strength in new platform launches and North America performance.
Opportunities lie in strategic initiatives, market demand confidence, and growth potential from new platforms.
Guidance adjustments reflect proactive measures to navigate uncertainties and drive future growth.
Overall, InMode remains resilient amidst challenges, poised for growth with strategic focus areas.

InMode reports Q2 revenue of $86.4 million, adjusts 2024 guidance

InMode faces challenges with declining demand for treatments and international sales, but is leveraging new platform launches and cost management to drive performance. The company is adapting to market conditions and geopolitical issues to capitalize on growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

InMode stock has significant upside potential due to its low valuation, profitability, share buybacks, and potential benefits from expected interest rate cuts. INMD's business model involves selling high-quality, expensive medical devices for aesthetic procedures, heavily influenced by interest rates due to customer financing. The stock's decline was driven by underutilized buybacks, declining revenue, and high interest rates, but recent buybacks and potential rate cuts offer a brighter outlook.

InMode Stock: An Inverse Bubble Caused By Short-Term Trouble

YOKNEAM, Israel , Sept. 4, 2024 /PRNewswire/ -- InMode Ltd.

InMode to Present at 2024 Baird Global Healthcare Conference

YOKNEAM, Israel , Aug. 6, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conferences and events in August: 9th Annual Needham Virtual MedTech & Diagnostics Conference Presenters: Moshe Mizrahy, Chief Executive Officer and Yair Malca, Chief Financial Officer Format: Virtual one-on-one meetings When: Monday, Aug. 12 Canaccord 44th Annual Global Growth Conference Presenters: Yair Malca, Chief Financial Officer Format: In-person fireside chat moderated by Caitlin Cronin, Director of MedTech Equity Research, and meetings When: Wednesday, Aug. 14 at 2:00 pm ET A live webcast of the presentation can be accessed here.

InMode to Present at Upcoming Investor Conferences

Q2 2024 revenue was $86.4 million, a 36.5% decrease from Q2 2023. GAAP net income fell to $23.8 million, down from $55.7 million in Q2 2023.

InMode Ltd. Revenue, Profit Plunge

Start Time: 08:30 January 1, 0000 9:07 AM ET InMode Ltd. (NASDAQ:INMD ) Q2 2024 Earnings Conference Call August 01, 2024, 08:30 AM ET Company Participants Moshe Mizrahy - CEO Michael Kreindel - Co-Founder and Chief Technology Officer Yair Malca - CFO Shakil Lakhani - President, North America Eran Krieger - Medical Director and VP of Medical Affairs Rafael Lickerman - Vice President, Finance Miri Segal - CEO, MS-IR Conference Call Participants Danielle Antalffy - UBS Caitlin Cronin - Canaccord Genuity Jeff Johnson - Baird Joseph Conway - Needham and Company Operator Good day, and welcome to InMode's Second Quarter 2024 Earnings Results Conference Call.

InMode Ltd. (INMD) Q2 2024 Earnings Call Transcript

InMode (INMD) came out with quarterly earnings of $0.34 per share, beating the Zacks Consensus Estimate of $0.30 per share. This compares to earnings of $0.72 per share a year ago.

InMode (INMD) Q2 Earnings and Revenues Top Estimates

YOKNEAM, Israel, Aug. 1, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the second quarter ended June 30, 2024.

InMode Reports Second Quarter 2024 Financial Results; Quarterly Revenue of $86.4M Represents 36.5% Year-Over-Year Decrease; Pro Forma Revenue (including new platform pre-orders not yet delivered) of $102.6M

IRVINE, Calif. , July 31, 2024 /PRNewswire/ -- InMode Ltd.

InMode Introduces IgniteRF The Complete Minimally Invasive Soft Tissue Contraction Platform

InMode (INMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate InMode (INMD) to Report a Decline in Earnings: What to Look Out for

Believes InMode's Cash Balance of Roughly 55% of its Market Cap is Grossly Inefficient Asserts the Current Valuation Offers an Unprecedented Opportunity to Create Shareholder Return MIAMI , July 25, 2024 /PRNewswire/ -- DOMA Perpetual Capital Management LLC today sent a letter to the Board of Directors of InMode (NYSE: INMD) urging the Board to execute a 40% tender offer of the stock.  The letter can be downloaded here.

DOMA Perpetual Sends Letter to the Board of Directors of InMode Urging the Execution of a 40% Tender Offer

IRVINE, Calif. , July 17, 2024 /PRNewswire/ -- InMode Ltd.

Morpheus8 Secures First and Only FDA Clearance for Soft Tissue Contraction for Fractional Radiofrequency Microneedling

Expects Q2 Revenue Between $86.2M-$86.3M, Pro-Forma Revenue (including new platform pre-orders) Between $102.4M-$102.5M, Decreases FY 2024 Guidance  to $430M-$440M Conference call to be held on Thursday, Aug. 1, 2024, at 8:30 a.m. Eastern Time YOKNEAM, Israel, July 11, 2024 /PRNewswire/ -- InMode Ltd.

InMode to Report Second Quarter 2024 Financial Results and Hold Conference Call on Aug. 1, 2024

Abbott Labs

Outset Medical

Fundamentally, few sectors exist outside of the broad healthcare umbrella that offer what I would term permanent relevance. In this case, the concept of caring for other people is likely an eternal one.

3 MedTech Stocks to Buy for Healthy Gains

Shareholders of InMode Ltd. have seen a 46% decline in value due to slowing sales and capital allocation uncertainties. Sales growth has been impacted by rising interest rates affecting leasing deals, leading to lower revenue growth projections for 2024. The company's new share repurchase program should reverse the dilution shareholders previously experienced.

InMode: Reversing Previous Shareholder Dilution With Buybacks

YOKNEAM, Israel , May 16, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Yair Malca, Chief Financial Officer and Spero Theodorou MD, Chief Medical Officer, will present in-person at the Jefferies Healthcare Conference in New York on June 5, 2024.

InMode to Present at Jefferies Healthcare Conference

IRVINE, Calif. , May 8, 2024 /PRNewswire/ -- InMode Ltd.

InMode Announces P1 Offshore Racing Partnership with Female Driver Victoria Rand

InMode (INMD) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.40 per share. This compares to earnings of $0.52 per share a year ago.

InMode (INMD) Q1 Earnings and Revenues Beat Estimates

Company Announces Share Repurchase Program of Up to 8.37 Million Shares; and Appoints New Chairman of the Board of Directors YOKNEAM, Israel, May 2, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the first quarter ended March 31, 2024.

InMode Reports First Quarter 2024 Financial Results; Quarterly Revenue of $80.3M Represents 24% Year-Over-Year Decrease; Pro Forma Revenue (including new platform pre-orders not yet available) of $96M;

Earnings Preview: InMode (INMD) Q1 Earnings Expected to Decline

NEW YORK, NY / ACCESSWIRE / April 15, 2024 / If you suffered a loss on your InMode Ltd. (NASDAQ:INMD) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/inmode-lawsuit-submission-form?prid=75664&wire=1 or contact Joseph E.

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 15, 2024 in InMode Lawsuit - INMD

NEW YORK , April 15, 2024 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of InMode Ltd. (NASDAQ: INMD) between June 4, 2021 and October 12, 2023, both dates inclusive (the "Class Period"), of the important April 15, 2024 lead plaintiff deadline.

INMD DEADLINE TODAY: ROSEN, LEADING TRIAL ATTORNEYS, Encourages InMode Ltd. Investors to Secure Counsel Before Important April 15 Deadline in Securities Class Action - INMD

NEW YORK, NY / ACCESSWIRE / April 15, 2024 / If you suffered a loss on your InMode Ltd. (NASDAQ:INMD) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/inmode-lawsuit-submission-form?prid=75642&wire=1 or contact Joseph E.

Levi & Korsinsky Reminds InMode Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 15, 2024 - INMD

LOS ANGELES, CA / ACCESSWIRE / April 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against InMode Ltd. ("InMode" or "the Company") (NASDAQ:INMD) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

IMPORTANT DEADLINE TODAY: The Schall Law Firm Encourages Investors in InMode Ltd. with Losses of $500,000 to Contact the Firm

NEW YORK, NY / ACCESSWIRE / April 15, 2024 / If you suffered a loss on your InMode Ltd. (NASDAQ:INMD) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/inmode-lawsuit-submission-form?prid=75581&wire=1 or contact Joseph E.

InMode Ltd. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 15, 2024 to Discuss Your Rights - INMD

YOKNEAM, Israel , April 15, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, responded to the recent petition to the U.S. Patent & Trademark Office filed by BTL Industries, Inc., in which BTL asks the USPTO to conduct an Inter Partes Review of InMode's U.S. Patent No.

News for Inmode Ltd Stock (INMD)